Literature DB >> 11409035

Secretases as therapeutic targets for the treatment of Alzheimer's disease.

D I Dominguez1, B De Strooper, W Annaert.   

Abstract

The extracellular deposition of short amyloid peptides in the brain of patients is thought to be a central event in the pathogenesis of Alzheimer's Disease. The generation of the amyloid peptide occurs via a regulated cascade of cleavage events in its precursor protein, A beta PP. At least three enzymes are responsible for A beta PP proteolysis and have been tentatively named alpha-, beta- and gamma-secretases. The recent identification of several of these secretases is a major leap in the understanding how these secretases regulate amyloid peptide formation. Members of the ADAM family of metalloproteases are involved in the non-amyloidogenic alpha-secretase pathway. The amyloidogenic counterpart pathway is initiated by the recently cloned novel aspartate protease named BACE. The available data are conclusive and crown BACE as the long-sought beta-secretase. This enzyme is a prime candidate drug target for the development of therapy aiming to lower the amyloid burden in the disease. Finally, the gamma-secretases are intimately linked to the function of the presenilins. These multi-transmembrane domain proteins remain intriguing study objects. The hypothesis that the presenilins constitute a complete novel type of protease family, and are cleaving A beta PP within the transmembrane region, remains an issue of debate. Several questions remain unanswered and direct proof that they exert catalytic activity is still lacking. The subcellular localization of presenilins in neurons, their integration in functional multiprotein complexes and the recent identification of additional modulators of gamma-secretase, like nicastrin, indicate already that several players are involved. Nevertheless, the rapidly increasing knowledge in this area is already paving the road towards selective inhibitors of this secretase as well. It is hoped that such drugs, possibly in concert with the experimental vaccination therapies that are currently tested, will lead to a cure of this inexorable disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409035     DOI: 10.3109/13506120109007356

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  4 in total

Review 1.  Implication of APP secretases in notch signaling.

Authors:  D Hartmann; J Tournoy; P Saftig; W Annaert; B De Strooper
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 2.  Immunization treatment approaches in Alzheimer's and prion diseases.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

3.  Characterization by Nano-Infrared Spectroscopy of Individual Aggregated Species of Amyloid Proteins.

Authors:  Jehan Waeytens; Vincent Van Hemelryck; Ariane Deniset-Besseau; Jean-Marie Ruysschaert; Alexandre Dazzi; Vincent Raussens
Journal:  Molecules       Date:  2020-06-24       Impact factor: 4.411

Review 4.  Non-Catalytic Roles of Presenilin Throughout Evolution.

Authors:  Grant P Otto; Devdutt Sharma; Robin S B Williams
Journal:  J Alzheimers Dis       Date:  2016-04-12       Impact factor: 4.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.